Algeta selects Onet to manufacture Alpharadin

Alpharadin, a highly targeted alpha-pharmaceutical, currently under clinical evaluation, is intended to improve survival in patients suffering from bone metastases from advanced cancer.

Algeta has chosen Onet for the final stages of the process, regarding the supply of a production line for the manufacturing of sterilized ready-to-use products.

Algeta president and CEOAndrew Kay Onet and Algeta are working together on the final stages of the commercial manufacturing process for Alpharadin to ensure that the product will be available to cancer patients with bone metastases, pending approval for this first-in-class alpha-pharmaceutical.